$45.23
0.79% yesterday
NYSE, Nov 25, 10:10 pm CET
ISIN
VGG111961055
Symbol
BHVN
Sector
Industry

Biohaven Pharmaceutical Holding Company Ltd. Stock price

$45.23
-7.61 14.40% 1M
+8.51 23.18% 6M
+2.43 5.68% YTD
+13.79 43.86% 1Y
-70.32 60.86% 3Y
-12.17 21.20% 5Y
+27.73 158.46% 10Y
NYSE, Closing price Mon, Nov 25 2024
-0.36 0.79%
ISIN
VGG111961055
Symbol
BHVN
Sector
Industry

Key metrics

Market capitalization $4.57b
Enterprise Value $4.22b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 13.58
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-848.89m
Free Cash Flow (TTM) Free Cash Flow $-531.06m
Cash position $379.40m
EPS (TTM) EPS $-9.35
P/E forward negative
Short interest 10.18%
Show more

Is Biohaven Pharmaceutical Holding Company Ltd. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Biohaven Pharmaceutical Holding Company Ltd. Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

15x Buy
100%

Analyst Opinions

15 Analysts have issued a Biohaven Pharmaceutical Holding Company Ltd. forecast:

Buy
100%

Financial data from Biohaven Pharmaceutical Holding Company Ltd.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 3.87 3.87
40% 40%
-
-3.87 -3.87
40% 40%
-
- Selling and Administrative Expenses 78 78
32% 32%
-
- Research and Development Expense 763 763
103% 103%
-
-845 -845
71% 71%
-
- Depreciation and Amortization 3.87 3.87
40% 40%
-
EBIT (Operating Income) EBIT -849 -849
71% 71%
-
Net Profit -804 -804
73% 73%
-

In millions USD.

Don't miss a Thing! We will send you all news about Biohaven Pharmaceutical Holding Company Ltd. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Biohaven Pharmaceutical Holding Company Ltd. Stock News

Negative
Reuters
about 24 hours ago
Biohaven said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve statistical significance compared to placebo and standard of care.
Neutral
PRNewsWire
one day ago
In the RESILIENT SMA study, taldefgrobep alpha showed clinically meaningful improvements in motor function at all timepoints on the Motor Function Measurement-32 scale (MFM-32), but the treatment arm did not statistically separate on the primary outcome at Week 48 compared to the placebo+standard of care (SOC) group. Efficacy signals were observed in clinically relevant and biomarker-defined su...
Neutral
PRNewsWire
14 days ago
Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial results from pivotal trial with troriluzole in spinocerebellar ataxia (SCA) Troriluzole 200 mg QD dosed orally in patients with SCA met the study's primary endpoint on the change from baseline on the modified functional Scale for the Assessme...
More Biohaven Pharmaceutical Holding Company Ltd. News

Company Profile

Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Head office Virgin Islands, British
CEO Vladimir Coric
Employees 239
Founded 2022
Website www.biohaven.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today